SAN DIEGO, Sept. 13 /PRNewswire-FirstCall/ -- Halozyme Therapeutics, Inc. , a biopharmaceutical company developing and commercializing products based on the extracellular matrix, today announced that Jonathan Lim, MD, Halozyme's President and Chief Executive Officer, will present at the UBS 2007 Global Life Sciences Conference to be held at the Grand Hyatt Hotel in New York on Monday, September 24, 2007 at 9:00 a.m. Eastern time (6:00 a.m. Pacific time).
Interested parties can access a live audio webcast and accompanying slide presentation via the Internet by visiting the Investor Relations section of the Company's Web site at http://www.halozyme.com. Archived presentations will be available on the Web site for 30 days following the presentation.
About Halozyme Therapeutics, Inc.
Halozyme is a biopharmaceutical company developing and commercializing products based on the extracellular matrix for the drug delivery, oncology, and dermatology markets. The company's portfolio of products is based on intellectual property covering the family of human enzymes known as hyaluronidases. The company's Enhanze(TM) Technology is a novel drug delivery platform designed to increase the absorption and dispersion of biologics. Its first partnership is with Roche to apply Enhanze Technology to Roche's biological therapeutic compounds for up to 13 targets. In addition, the company has received FDA approval for two products: Cumulase(R) and HYLENEX, for use as an adjuvant to increase the absorption and dispersion of other injected drugs and fluids. HYLENEX is partnered with Baxter Healthcare Corporation. The Company also has a number of different enzymes in its portfolio that are targeting significant areas of unmet need.
Halozyme Contact Investor Relations Contact David A. Ramsay Don Markley Chief Financial Officer Lippert/Heilshorn & Associates (858) 794-8881 (310) 691-7100 dramsay@halozyme.comdmarkley@lhai.com
Halozyme Therapeutics, Inc.CONTACT: David A. Ramsay, Chief Financial Officer of HalozymeTherapeutics, Inc., +1-858-794-8881, dramsay@halozyme.com; or InvestorRelations, Don Markley of Lippert-Heilshorn & Associates, +1-310-691-7100,dmarkley@lhai.com, for Halozyme Therapeutics, Inc.
Web site: http://www.halozyme.com/
